CytomX Therapeutics (NASDAQ:CTMX) Posts Quarterly Earnings Results, Beats Estimates By $0.45 EPS

CytomX Therapeutics (NASDAQ:CTMX) issued its quarterly earnings results on Thursday. The biotechnology company reported $0.22 earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.45, Zacks reports. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%.

CytomX Therapeutics Stock Performance

CTMX stock traded up $0.00 during mid-day trading on Thursday, reaching $0.62. 902,249 shares of the stock traded hands, compared to its average volume of 2,401,818. CytomX Therapeutics has a one year low of $0.60 and a one year high of $5.85. The stock has a market capitalization of $48.31 million, a PE ratio of 3.63 and a beta of 1.01. The business has a 50-day moving average price of $0.86 and a two-hundred day moving average price of $1.03.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a research report on Tuesday, January 7th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $5.77.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.